ANZCTR search results

Psilocybin is proposed to act via a loosening of cognitive control processes thereby rectifying deeply engrained patterns of thought and behaviour to promote cognitive flexibility. There is also evidence that psychedelics (psilocybin & LSD) alter dopaminergic reward signalling in healthy participants, but whether or not this is associated with responses to food choice or food reward is unknown. This project with use brain imaging techniques to investigate the brain networks that integrate information about the nutritional state of the body (e.g., hunger, satiety) with decision-making systems important to food choice and how they are altered by psilocybin. To do this, we will acquire brain scans of healthy adults before and after they have been administered a single dose of psilocybin, while they are completing an in-scan food choice task using a custom designed liquid food delivery apparatus (a "gustometer"). This information is critical to inform the therapeutic application of psilocybin in eating disorders such as anorexia nervosa, in which patients experience aberrant food reward processing that contributes to their disorder maintenance and relapse. Clinical trials in this patient population are already underway, underscoring the important of obtaining this critical information in a timely manner.

This study will evaluate the role of FAPI-46 (Fibroblast activation protein inhibitor) PET (positron emission tomography) imaging in prognosis and response to immunotherapy in metastatic cancers Who is it for? You may be eligible to join this study if you are aged 18 years and above, have histologically confirmed metastatic head and neck squamous cell carcinoma, hepatocellular carcinomas, mesothelioma, non-small cell lung cancers and planned for immunotherapy containing regimen only. Study details All participants in this study will have FAPI-46 PET imaging performed before immunotherapy treatment. We will also assess FAP expression via immunohistochemistry on the available tissue samples that were already taken for diagnosis. Correlation of FAP expression in tumour samples via immunohistochemistry and FAP expression on imaging will be assessed. This research will help provide insight in the role of FAPI-46 PET scan and FAP in predicting prognosis and could be a stepping stone for future applications in potential targeted treatment and theranostics.

The GenI-AIRSPACE trial aims to understand how genetic testing results influence decisions for people with favourable intermediate-risk prostate cancer. We want to see if these test results can help us safely recommend active surveillance for those with lower genetic risk or suggest treatment if their cancer is more likely to progress. Who is it for? You may be eligible for this study if you are aged 18 years or older with a histological diagnosis of prostate adenocarcinoma with no evidence of metastatic disease, and your treating doctor has recommended ‘active surveillance’, as an alternative to having surgery or radiation therapy now. Almost half of the new prostate cancers diagnosed each year in Australia are referred to as being of ‘favourable intermediate risk,’. This classification indicates that progression to treatments such as surgery or radiation can, in some circumstances, be deferred and the cancer safely monitored over time. This classification is based on results from routine tests, including biopsy results, diagnostic tests like bone or CT scans, and prostate specific antigen or PSA blood tests. Study details Eligible participants will be randomly assigned to one of two groups: the standard of care treatment group which continue in usual care with their treating doctor, or the genomically informed group who will undergo genetic tests to be classified as either high risk or low risk for their cancer to progress. To conduct the genetic tests, the study team will request access to tissue samples from previous prostate cancer biopsies and a fresh10mL blood sample (about 2 teaspoons) will be collected. The results of these tests will be provided with no explicit treatment recommendation. Instead, the information will be provided to both the participant and the treating doctor, and any treatment decisions will be made through shared decision-making. This is a randomised trial, and each participant will have an equal chance (50%) of being allocated into each group. The group assignment will be decided by a computer, so neither the participant nor the doctor can choose the group Both groups will answer questions about their quality of life at the start of the trial, then every six months for a year, and then once a year after that. They will be followed for up to ten years to see if they start treatment for prostate cancer, whether the disease has progressed, and if it has spread. It is hoped that findings from this study will help determine the utility of genomic screening in individualising treatment pathways for people diagnosed with intermediate-risk prostate cancer, and help lessen the number of people who get intense treatment, without hurting their long-term health outcomes.

This multi-method evaluation will evaluate the feasibility, acceptability, and effectiveness of a caregiver wellbeing program delivered by CaFHS in South Australia. The caregiver wellbeing program will deliver evidence-informed caregiver wellbeing psychoeducation into these routine services. Our evaluation aims to determine whether the caregiver wellbeing program is feasible and acceptable to deliver within these routine services and whether it is effective in improving the wellbeing of caregivers. To achieve our aims, we will conduct pre- and post- program surveys and focus groups with caregivers who participated in the program, and staff who were involved in implementing or delivering the program. To support and evaluate a future statewide roll out, this study will also evaluate the feasibility of conducting a definitive trial.

Decompensated cirrhosis is associated with high morbidity and mortality as well as high resource utilisation and healthcare costs. This study aims to provide evidence for a novel intervention to reduce hospitalisation in this vulnerable cohort. We hypothesise that continuous terlipressin infusion will be more effective than weekly albumin infusions in the prevention of decompensating liver events in cirrhosis

This project aims to investigate resident and family engagement in communicating about psychotropic medicines by developing and testing creative strategies in aged care facilities. Psychotropic medicines affect the mind, emotions and behaviour of individuals. The project will involve the conduct of interviews and observations, which will help to inform the conduct of co-design panels. Strategies developed from co-design panels will be evaluated in a feasibility and acceptability trial. Knowledge dissemination of the results will occur with audio scenario interviews, development of infographics and workshops at the aged care sites.

The aim of the study is to develop and test tailored co-designed strategies that are agreed upon between hospitalised older people, their families and health professionals in managing medications as patients move across transitions of care. Strategies developed from feedback events and co-design group workshops, will be tested in a feasibility and acceptability trial. The work will inform the future development and testing of a randomised controlled trial of co-designed engagement strategies.

The main aim of the study is to evaluate the safety, PK, and PD effects of SEP 786 in healthy participants. The results of this study will help inform the dosing and frequency of dosing in participants with hypoparathyroidism, which is the anticipated main therapeutic use for SEP-786.

This project aims to evaluate the role of the relative motion flexion orthosis in recovery of proximal interphalangeal joint (PIPJ) extension following hand injury or surgery. Participants who have 20 degrees or more PIPJ extension deficit, and satisfy the other inclusion criteria, will be eligible to participate. They will be randomised into two groups; usual care, or usual care with the addition of the relative motion orthosis. Assessments will be completed at baseline and six weeks post commencement of intervention. We hypothesise that the intervention group will have greater PIPJ extension at six weeks, compared to the control group.

Falls in hospital remain a common and costly problem but due to the complex intrinsic and extrinsic factors involved, no single approach or intervention has proved a panacea. This stepped wedge type I hybrid effectiveness-implementation trial will evaluate whether supported implementation (via quality improvement coaching and other tailored strategies) of tailored ward-based fall prevention interventions reduces patient falls in hospitals (primary objective). The impact of supported implementation of tailored ward-based fall prevention interventions on other fall related outcomes (e.g. falls injuries, unwitnessed falls), hospital acquired complications (e.g. pressure injuries and delirium), patient hospital length of stay, staff professional fulfilment and on a range of implementation outcomes and determinants will also be evaluated, as will the cost-effectiveness of the intervention. Routinely collected data from patient medical records and hospital databases will inform the primary outcome measure of rate of falls and some secondary effectiveness outcomes. Pre and post implementation patient and staff surveys, bedside audits and semi-structured interviews will inform secondary effectiveness and implementation outcomes. The primary hypothesis of this study is that supported implementation of tailored ward-based fall prevention interventions will reduce the rate of patient falls.